Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Mineralys Therapeutics in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, completed a US$40...
You must be a Standard 1 Year member to access this content.
